₹-0.90
(Market cap
₹156 Cr
Revenue (TTM)
₹249 Cr
P/E Ratio
13.3
P/B Ratio
1.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹12 Cr
-
ROE
14.9 %
-
ROCE
14.7 %
-
Industry P/E
36.04
-
EV/EBITDA
7.4
-
Debt to Equity
0.2
-
Book Value
₹82.8
-
EPS
₹11.2
-
Face value
10
-
Shares outstanding
11,485,616
10 Years Aggregate
CFO
₹133.82 Cr
EBITDA
₹155.03 Cr
Net Profit
₹45.34 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Parnax Lab
| 4.6 | -8.1 | 11.0 | 37.3 | 30.1 | 38.3 | 16.7 |
|
BSE Healthcare
| 11.8 | 2.7 | 16.0 | 12.6 | 24.9 | 14.4 | 12.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Parnax Lab
| -22.9 | 90.8 | 21.1 | 38.0 | 91.7 | 76.6 | -62.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Parnax Lab
|
136.0 | 156.2 | 248.6 | 11.8 | 7.7 | 13.9 | 13.3 | 1.6 |
| 3,180.4 | 40,113.7 | 5,452.9 | 1,056.0 | 22.4 | 25.4 | 38 | 8.9 | |
| 8,391.0 | 20,997.5 | 2,275.6 | 187.5 | 10.3 | 22.9 | 112 | 24.1 | |
| 2,506.4 | 19,109.3 | 2,187.2 | 649.7 | 31.5 | 19 | 29.8 | 5.3 | |
| 1,893.3 | 11,573.9 | 1,403.2 | 185.1 | -- | 27.4 | 62.5 | 15.5 | |
| 1,459.0 | 20,230.8 | 3,129.4 | 647.4 | 26.9 | 18.1 | 32.7 | 5.2 | |
| 2,243.9 | 35,820.7 | 4,147.8 | 709.5 | 22.3 | 19.1 | 50.5 | 8.6 | |
| 4,460.7 | 20,429.6 | 2,519.7 | 722.4 | 33.6 | 18.8 | 28.3 | 4.9 | |
| 6,232.5 | 10,362.3 | 1,408.0 | 326.9 | 30.8 | 57.1 | 31.7 | 19.8 | |
| 571.6 | 11,178.5 | 1,538.1 | 226.2 | 20.4 | 9 | 45.9 | 4.3 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Parnax Lab
Manufacture of allopathic pharmaceutical preparations
-
Incorporated
1982
-
Chairman
--
-
Managing Director
Mihir Shah
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
FAQs for Parnax Lab
What is the current share price of Parnax Lab Ltd Today?
The share price of Parnax Lab Ltd is ₹136.00 (BSE) as of 25-Jun-2026 IST. Parnax Lab Ltd has given a return of 30.11% in the last 3 years.
What is the current PB & PE ratio of Parnax Lab Ltd?
The P/E ratio of Parnax Lab Ltd is 13.26 times as on 25-Jun-2026, a 63 discount to its peers’ median range of 36.04 times.
The P/B ratio of Parnax Lab Ltd is 1.64 times as on 25-Jun-2026, a 67 discount to its peers’ median range of 4.91 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
10.67
|
1.48
|
|
2024
|
15.48
|
2.08
|
|
2023
|
6.94
|
0.96
|
|
2022
|
15.68
|
2.79
|
|
2021
|
0.00
|
0.51
|
What is the 52 Week High and Low of Parnax Lab Ltd?
The 52-week high and low of Parnax Lab Ltd are Rs 182.00 and Rs 96.25 as of 25-Jun-2026.
What is the market cap of Parnax Lab Ltd?
Parnax Lab Ltd has a market capitalisation of ₹ 156 Cr as on 25-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Parnax Lab Ltd?
Before investing in Parnax Lab Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.